Lutein and Alzheimer's Disease Study

Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00596024

Acronym

LAD

Enrollment

Registered

2008-01-16

Start date

2007-12-31

Completion date

2009-07-31

Last updated

2019-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients. The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.

Interventions

DIETARY_SUPPLEMENTlutein/zeaxanthin

daily supplementation of lutein and zeaxanthin at dose of 12 mg/day

DIETARY_SUPPLEMENTplacebo

placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosed with moderately severe Alzheimer's disease

Design outcomes

Primary

Measure	Time frame
oxidative damage markers	3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026